SARS-CoV-2/Renin–angiotensin system: Deciphering the clues for a couple with potentially harmful effects on skeletal muscle
Author
dc.contributor.author
González, Andrea
Author
dc.contributor.author
Orozco Aguilar, Josué
Author
dc.contributor.author
Achiardi, Óscar
Author
dc.contributor.author
Simon, Felipe
Author
dc.contributor.author
Cabello Verrugio, Claudio
Admission date
dc.date.accessioned
2021-05-04T21:55:32Z
Available date
dc.date.available
2021-05-04T21:55:32Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Int. J. Mol. Sci. 2020, 21, 7904
es_ES
Identifier
dc.identifier.other
10.3390/ijms21217904
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/179428
Abstract
dc.description.abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV-2) has produced significant health emergencies worldwide, resulting in the declaration by the World Health Organization of the coronavirus disease 2019 (COVID-19) pandemic. Acute respiratory syndrome seems to be the most common manifestation of COVID-19. A high proportion of patients require intensive care unit admission and mechanical ventilation (MV) to survive. It has been well established that angiotensin-converting enzyme type 2 (ACE2) is the primary cellular receptor for SARS-CoV-2. ACE2 belongs to the renin-angiotensin system (RAS), composed of several peptides, such as angiotensin II (Ang II) and angiotensin (1-7) (Ang-(1-7)). Both peptides regulate muscle mass and function. It has been described that SARS-CoV-2 infection, by direct and indirect mechanisms, affects a broad range of organ systems. In the skeletal muscle, through unbalanced RAS activity, SARS-CoV-2 could induce severe consequences such as loss of muscle mass, strength, and physical function, which will delay and interfere with the recovery process of patients with COVID-19. This article discusses the relationship between RAS, SARS-CoV-2, skeletal muscle, and the potentially harmful consequences for skeletal muscle in patients currently infected with and recovering from COVID-19.
es_ES
Patrocinador
dc.description.sponsorship
National Fund for Science and Technological Development
FONDECYT 1200944
1201039
Millennium Institute on Immunology and Immunotherapy
P09-016-F
Basal Grant-CEDENNA from The National Research and Development Agency (ANID), Government of Chile
AFB180001
Iniciativa Cientifica Milenio (ANID, Chile)
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT
1200944